Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study
详细信息 查看全文
- 作者：Sté ; phane Oudarda ; stephane.oudard@aphp.fr" class="auth_mail" title="E-mail the corresponding author ; Lionnel Geoffroisb ; Aline Guillotc ; Christine Chevreaud ; Jean-Laurent Devillee ; Sabrina Falkowskif ; Helen Boyleg ; Marjorie Baciuchkah ; Pierre Gimeli ; Brigitte Laguerrej ; Mathieu Laramask ; Christian Pfisterl ; Delphine Topartm ; Fré ; dé ; ric Rollandn ; Eric Legouffeo ; Gwé ; naë ; l Denecherep ; Eric Yaovi Amelaq ; Sophie Abadie-Lacourtoisier ; Marine Gross-Goupils
- 关键词：First-line ; Metastatic renal cell carcinoma ; Rechallenge ; Resistance ; Sunitinib
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：62
- 期：Complete
- 页码：28-35
- 全文大小：465 K
文摘
- •
Sunitinib rechallenge in metastatic renal cell carcinoma patients was assessed.
- •
Median PFS was 18.4 and 7.9 months with first-line sunitinib and rechallenge.
- •
Sunitinib rechallenge safety was as expected with no new adverse events reported.
- •
Sunitinib rechallenge is feasible with potential clinical benefit.
- •
Initial progression with sunitinib may not be associated with absolute resistance.